Corporate Profile

Entera is a leader in the development of orally delivered macromolecules, including peptides and other therapeutic proteins. The Company focuses on significant unmet medical needs where a mini daily tablet form of a peptide treatment or replacement therapy holds the potential to transform the standard of care. The Company’s most advanced product candidates, EB613 for the treatment of high risk, post-menopausal osteoporosis and EB612 for the treatment of hypoparathyroidism, are in clinical development.

INVESTOR MEDIA

Press Releases

  • May 05, 2023

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

  • May 03, 2023

Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

  • Apr 26, 2023

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board

Recent Events

  • Feb 16, 2023 8:00 AM EST

SVB Securities Global Biopharma Conference

Click here for Webcast
  • Sep 28, 2022

Entera KOL Event

  • May 18, 2022 8:00 AM EDT

First Quarter 2022 Financial Results Call

SEC Filings

Filing Date Description View

Quarterly report which provides a continuing view of a company's financial position
View HTML
0001178913-23-001715.pdf
0001178913-23-001715.rtf
0001178913-23-001715.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Report of unscheduled material events or corporate event
View HTML
0001178913-23-001714.pdf
0001178913-23-001714.rtf
0001178913-23-001714.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Statement of changes in beneficial ownership of securities
View HTML
0001178913-23-001531.pdf
0001178913-23-001531.rtf
0001178913-23-001531.xls

CORPORATE GOVERNANCE

Board of Directors
Management
Committee Composition